chartexchange

MRUS
Merus N.V. Common Shares
stockNASDAQ

InactiveDec 29, 2025
90.00USD-7.140%(-6.92)2,728,077
Loading…
Loading…
Sector
Healthcare
Industry
Biotechnology
HQ
Utrecht, Utrecht, Netherlands
MRUS Profile

merus is developing best-in-class therapeutics to treat and potentially cure cancer patients. our most advanced development programs use the biclonics® format. biclonics® are capable of simultaneously attacking tumors in multiple ways. for example by activating the immune system to kill tumor cells and directly inhibiting tumor cell growth and survival pathways.

MRUS Performance
PeriodPriceDateChange